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AbstrAct
It is now widely accepted that therapeutic antibodies targeting epidermal growth 
factor receptor (EGFR) can have efficacy in KRAS wild-type advanced colorectal cancer 
(CRC) patients. What remains to be ascertained is whether a subgroup of KRAS-mutated 
CRC patients might not also derive benefit from EGFR inhibitors. Metalloproteinase 
inhibitor 1 (TIMP-1) is a pleiotropic factor predictive of survival outcome of CRC 
patients. Levels of TIMP-1 were measured in pre-treatment plasma samples (n = 426) 
of metastatic CRC patients randomized to Nordic FLOX (5-fluorouracil and oxaliplatin) 
+/− cetuximab (NORDIC VII study). Multivariate analysis demonstrated a significant 
interaction between plasma TIMP-1 protein levels, KRAS status and treatment with 
patients bearing KRAS mutated tumors and high TIMP-1 plasma level (> 3rd quartile) 
showing a significantly longer overall survival if treated with cetuximab (HR, 0.48; 
95% CI, 0.25 to 0.93). To gain mechanistic insights into this association we analyzed 
a set of five different CRC cell lines. We show here that EGFR signaling induces TIMP-1  
expression in CRC cells, and that TIMP-1 promotes a more aggressive behavior, 
specifically in KRAS mutated cells. The two sets of data, clinical and in vitro, are 
complementary and support each other, lending strength to our contention that 
TIMP- 1 plasma levels can identify a subset of patients with KRAS-mutated metastatic 
CRC that will have benefit from EGFR-inhibition therapy.
                   Research Paper
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IntroductIon
Different types of treatment are available for patients 
with advanced metastatic colorectal cancer (mCRC), 
including targeted biological treatment. Nonetheless, there 
is a continued unmet need for effective, and fast, point-of-
care tests for predictive biomarkers in order to select the 
right treatment for individual patients. Epidermal growth 
factor receptor (EGFR) is recognized as a key factor in 
colorectal cancer (CRC) development and progression 
due to its effects on tumor-promoting processes, such 
as cellular proliferation, survival, and motility [1–5]. 
It is therefore not surprising that this receptor tyrosine 
kinase has become a major therapeutic target, with 
several approved anti-EGFR drugs currently being used 
in the clinic, including the antibodies cetuximab and 
panitumumab [6, 7]. However, only few patients have 
long-term responses to these agents, with clinical benefit 
almost always curtailed by the development of acquired 
drug resistance. At the moment, it is thought that anti-
EGFR antibodies function at two levels: i) by preventing 
ligand-induced activation of downstream effectors that 
mediate intracellular signaling pathways, such as the RAS/
RAF mitogen-activated protein kinase (MAPK) pathway, 
or phosphoinositide 3-kinase (PI3K)/ protein kinase B 
(AKT) pathway [4, 6], and ii) by triggering antibody-
dependent cellular cytotoxicity (ADCC) [8, 9]. As one 
may expect, resistance to anti-EGFR antibodies can occur 
through functional alterations at any of these levels. Thus, 
activating mutations in downstream effectors, such as 
RAS, RAF, or PI3KCA, can result in persistent growth 
signaling, and provide a functional bypass of EGFR-
blockade. In addition, KRAS mutations can also impair 
the therapeutic effect of cetuximab-induced ADCC [9, 10]. 
Concordantly, only KRAS wild-type (wt) patients seem 
to derive full benefit from anti-EGFR therapy, and as a 
consequence, clinical use of cetuximab and panitumumab 
in CRC is currently restricted to patients bearing KRAS 
wt tumors [11–16]. However, there are a number of 
discordant findings, with in vitro and in vivo data 
suggesting that some patients with KRAS mutated tumors 
may actually still have benefit from cetuximab treatment 
[12, 13, 17–19]. Conversely, response rates to cetuximab 
combination regimens are about 40% in the best of cases 
– including patients with no mutations at all in KRAS, 
BRAF, NRAS, and PIK3CA exon 20 [12]. Clearly, there are 
a number of confounding factors, such as the exact nature 
of KRAS mutations (G13D or other), levels of EGFR 
expression, EGFR mutations, first or later lines of therapy, 
chemotherapeutic backbone (irinotecan or oxaliplatin), or 
even administration regimen (infusion or bolus), which all 
seem to interplay and ultimately can affect the outcome 
of anti-EGFR therapy in CRC patients. Thus, additional 
predictive biomarkers are needed to improve stratification 
of patients with mCRC to EGFR inhibitor therapies.
TIMP-1 is a 28 kDa glycoprotein that can be found 
in the extracellular compartment in several tissues, and 
is present in various body fluids [20]. TIMP-1 is one 
of four (TIMP-1 through 4) human natural endogenous 
inhibitors of matrix metalloproteinases (MMPs), a group 
of peptidases involved in degradation of the extracellular 
matrix. In addition to its function as inhibitor of MMPs, 
TIMP-1 can have tumor-promoting effects, including 
stimulation of cell proliferation, induction of anti-
apoptotic signaling, and support of angiogenesis [21–24]. 
Plasma TIMP-1 is elevated in patients with CRC [20, 25] 
and high plasma TIMP-1 levels have consistently been 
associated with poor prognosis in patients with primary 
or advanced CRC [25–29]. In this respect it should be 
noted that an association between TIMP-1 expression 
and EGFR signaling has also been observed in various 
cellular contexts [30–35], and is found to occur, at least 
under certain circumstances, via NF-κB signaling, in a 
MEK-independent manner [36]. Taken together, these 
data raised the possibility of an association between 
EGFR signaling, TIMP-1 expression and response to anti-
EGFR agents. We show here that TIMP-1 plasma levels 
were associated with patient outcome in mCRC, and that 
patients bearing KRAS-mutated tumors and high TIMP-1 
plasma level (> 3rd quartile) showed a significantly longer 
overall survival when treated with cetuximab (HR 0.48; 
95% CI, 0.25 to 0.93), as compared to patients with KRAS 
mutated tumors not treated with cetuximab. These results 
were substantiated in preclinical cellular models, where 
we found that exposure of CRC cell lines to recombinant 
TIMP-1 (rTIMP-1) promoted a more aggressive behavior, 
specifically in KRAS mutated cells. Taken together, these 
data indicate that plasma TIMP-1 levels, which can be 
measured with a simple and non-invasive point-of-care 
test, may be useful for selection of patients bearing KRAS 
mutated tumors that will derive benefit from EGFR-
inhibition therapy.
rEsuLts
Given that previous work from our group, as 
well as from other groups, had shown that TIMP-1 can 
be predictive of outcome in CRC [20, 29–31], and that 
TIMP-1 can promote cancer cell survival through the 
PI3K/AKT signaling axis [32, 33], we reasoned that 
TIMP-1 could influence response to anti-EGFR therapy. 
To address this question, we tested interactions between 
plasma TIMP-1 levels and EGFR targeted treatment in a 
clinical setting.
Pre-treatment plasma tIMP-1 and associations 
to progression-free survival and overall survival
Plasma samples from patients enrolled in the 
NORDIC VII study were available to us. The NORDIC VII 
study was a three-arm, phase III prospective randomized 
clinical trial, of anti-EGFR therapy (cetuximab) [34]. The 
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design of this study, A versus A+B where cetuximab is B, 
lends itself to studies on predictive biomarkers for 
cetuximab effects.
To address the possibility of an association between 
EGFR signaling, TIMP-1 expression and response to anti-
EGFR agents, we measured total plasma TIMP-1 levels 
(free and in complex with matrix metalloproteinase) in the 
426 samples that were available from the study (Figure S1), 
using an ELISA assay developed in-house [35]. 
The two study populations (+/− cetuximab) were similar 
and not different from the total intention to treat population 
of 566 patients. The median pre-treatment plasma 
TIMP-1 was 269 ng/mL (58 to 1318 ng/mL) with no 
differences between the two treatment groups (P = 0.97). 
Tumors were KRAS mutated in 147 patients (39%). There 
was no association between pre-treatment plasma TIMP-1 
and gender, or number of metastatic sites. There were 
statistically significant associations between pre-
treatment plasma TIMP-1 and WHO performance status 
(PS), location of the primary tumor, previous adjuvant 
chemotherapy, KRAS and BRAF status. The highest 
plasma TIMP-1 values were found in patient with 
high WHO PS, primary tumor in colon, no adjuvant 
therapy, KRAS wild-type tumors and BRAF mutated 
tumors (Table 1). Univariate Cox analyses including 
all patients showed that high pre-treatment plasma 
TIMP-1 was significantly associated with shorter 
progression-free survival (PFS) (HR, 1.22; 95% CI, 
1.07 to 1.39; P = 0.003), and overall survival (OS) 
(HR, 1.55; 95% CI, 1.33 to 1.80; P < 0.0001) (Table 2). 
Kaplan-Meier estimates of survival probabilities for 
PFS and OS stratified by pre-treatment plasma TIMP-1 
levels are shown in Figure 1A and 1B, respectively. 
Multivariate analysis (plasma TIMP-1, KRAS and BRAF 
status, serum CRP, serum CEA, WHO PS, number of 
metastatic sites, age, and gender) demonstrated that high 
plasma TIMP-1 was an independent biomarker of short 
OS (HR, 1.35; 95% CI, 1.12 to 1.62; P = 0.016) while a 
significant interaction between plasma TIMP-1 and KRAS 
mutational status could not be demonstrated (P = 0.47). 
Plasma TIMP-1 was not significantly associated to PFS in 
this multivariate model (P = 0.82).
Pre-treatment plasma TIMP-1 and benefit from 
cetuximab treatment
To determine if there was an association between 
TIMP-1 and response to cetuximab, we examined TIMP-1 
plasma levels in patients responding, or not, to cetuximab. 
Pre-treatment plasma TIMP-1 levels were not significantly 
different in non-responders versus responders (median 
282 µg/l vs. 260 µg/l; OR, 1.16; 95% CI, 0.91 to 1.49; 
P = 0.23) when looking at all patients and independently 
of KRAS status. Multivariate analysis showed a trend for 
an association between RR and pre-treatment plasma 
TIMP-1 (OR, 1.34; 95% CI, 0.99 to 1.82; P = 0.059). A 
significant interaction between RR, cetuximab treatment, 
KRAS mutational status, and TIMP-1 could not be shown 
(P = 0.48). The results of the multivariate model for OS 
including pre-treatment plasma TIMP-1, KRAS and BRAF 
status, age, gender, CRP, CEA, WHO PS, number of 
metastatic sites and treatment, or not, with cetuximab are 
shown in Table 2. A significant 3-ways interaction between 
treatment (+/− cetuximab), KRAS mutational status, 
and plasma TIMP-1 baseline level was demonstrated 
(P = 0.006). The HR for plasma TIMP-1 for patients with 
KRAS mutant tumors not treated with cetuximab was 
4.45 (95% CI, 1.73 to 11.48) compared to 1.04 (95% CI, 
0.76 to 1.42) if treated with cetuximab. A comparison 
of patients treated with cetuximab versus those not 
treated with cetuximab for the KRAS mutant subgroup 
showed a longer OS (HR, 0.48, 95% CI, 0.25 to 0.93) 
if the plasma TIMP-1 level was relatively high (3rd 
quartile), whereas the opposite was found for those with 
low levels of plasma TIMP-1. There was no significant 
interaction between plasma TIMP-1 levels, treatment, and 
OS in patients with KRAS wild-type tumors (Table 2). 
Multivariate analysis of PFS could not demonstrate a similar 
significant association to plasma TIMP-1 (P = 0.078), 
however the analysis suggests a pattern similar to that 
seen for OS (Table 2). The above described effects 
between plasma TIMP-1 levels, treatment and OS, are 
illustrated in Figure 2A and 2B, respectively. Patients 
were stratified into eight groups according to treatment 
(received cetuximab or not), KRAS status (wt or mutant), 
and TIMP-1 level (below 201 ng/ml or above 409 ng/ml). 
Kaplan-Meier plots of OS showed that KRAS mutated 
patients, with plasma TIMP-1 levels above 409 ng/ml 
had a significantly worse outcome if not treated with 
cetuximab (stipled red line) as compared to those that 
did receive cetuximab (solid red line) (Figure 2A). 
Conversely, KRAS mutated patients, with plasma TIMP-1 
levels below 201 ng/ml showed no significant difference 
in outcome, whether treated or not with cetuximab 
(solid and stipled black lines, respectively) (Figure 2A). 
Estimation of OS probabilities based on the full 
multivariable Cox regression model (taking into account 
the covariates CEA and CRP status, gender, age, multiple 
metastatic sites, performance status, and BRAF status), 
verified the association between KRAS status, plasma 
TIMP-1 levels, and response to cetuximab (Figure 2B, 
compare KRAS mutated patients, with high plasma 
TIMP-1 levels, stipled red line, with those that received 
cetuximab, solid red line).
EGF induces tIMP-1 expression in crc cell lines
To gain mechanistic insights into the association 
we found between TIMP-1 expression and benefit 
from cetuximab treatment in KRAS-mutated patients, 
we analyzed the effect(s) of TIMP-1 on CRC cells. 
Previous studies have shown that EGF stimulates TIMP-1 
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expression in extravillous trophoblasts and thyroid 
carcinoma cells [36, 37]. To ascertain the relevance of 
this interaction in CRC, we investigated the effect of EGF 
stimulation on TIMP-1 expression in cellular models of 
CRC. We analyzed five different CRC cell lines: SW620 
(KRAS G12V, BRAF wt), Colo-205 (KRAS wt, BRAF 
V600E), HT-29 (KRAS wt, BRAF V600E), HCT-15 (KRAS 
G13D, BRAF wt), and DLD-1 (KRAS G13D, BRAF wt), 
for TIMP-1 expression upon stimulation with EGF. As 
shown in Figure 3, four of the five cell lines (Colo-205, 
HT-29, HCT-15, and DLD-1, respectively) showed 
increased, albeit to a varying degree, TIMP-1 expression 
upon stimulation with EGF. This effect was dose-
dependent, as stimulation with 50 ng/mL EGF generally 
elicited relatively higher levels of TIMP-1 expression 
than 10 ng/mL (Figure 3, compare 10 ng/mL EGF with 
50 ng/mL EGF), and was not associated with KRAS 
or BRAF status. In all cases phosphorylation of AKT 
at Ser374 was used as a measure of functional EGF 
signaling. In the cases of HCT-15 and HT-29 we found 
high basal levels of AKT phosphorylation even under 
serum-starvation growth conditions, consistent with the 
presence of activating mutations in BRAF and KRAS, 
respectively (Figure 3A and 3B, respectively). However, 
we could observe increased AKT phosphorylation after 
24 h of ligand stimulation of EGFR, indicating that 
the stimulatory potential of the signaling pathway was 
maintained, and thus the increase in TIMP-1 expression 
following EGF stimulation could be ascribed to stimuli 
transduced through the EGFR signaling axis in HCT-15 
and HT-29. Following 48 h of EGF stimulation, we 
observed a continued dose-dependent EGF-induced 
increase in TIMP-1 expression (Figure 3A–3C). Given 
the variable range in relative increases in TIMP-1 
expression between the various cell lines in response to 
EGF stimulation, we analyzed EGFR expression in the five 
CRC cell lines we used. We found that these cells lines 
had very different levels of EGFR expression (Figure S2), 
and that the levels of EGFR expression in the five cell 
lines were consistent with the effect of EGF on TIMP-
1 expression we had observed. Thus, HT29 (strong 
EGFR expression), and HCT15 and DLD1 (moderate 
EGFR expression) cells, displayed up-regulation of 
TIMP-1 expression upon exposure to EGF, whereas Colo-
205 (weak EGFR expression), and SW620 (no detectable 
EGFR), showed very limited or no increase in TIMP-1 
expression, respectively (Figure 3). We concluded that, 
overall, TIMP-1 expression is under regulation of the 
EGF-EGFR signaling axis in the cellular models of CRC 
we analyzed.
tIMP-1 promotes colony formation in soft agar 
in KRAS-mutated cells only
In order to further assess the biological effects 
of TIMP-1 on CRC cells, and its association to KRAS 
mutational status, we performed an anchorage-independent 
growth analysis of a matched pair of isogenic DLD-1 
table 1: demographic and baseline clinical characteristics of the 426 patients with metastatic 
colorectal cancer included in the nordic VII study for whom pre-treatment plasma tIMP-1 was 
measured
Variable N (%) Median plasma tIMP-1 (range)
P-value for 
Wilcoxon test 
Gender Males
Females
253 (59)
173 (41)
278 (58–1318)
259 (86–1317)
0.14
WHO PS 0
1
2
295 (69)
118 (28)
13 (3)
237 (58–1317)
339 (123–1317)
524 (228–1318)
< 0.0001
Location Colon
Rectum
250 (59)
176 (41)
282 (58–1317)
251 (84–1318)
0.018
Number of metastatic 
sites
1
> 1
124 (29)
302 (71)
232 (87–1318)
277 (58–1317)
0.046
Adjuvant 
chemotherapy
Yes
No
38 (9)
388 (91)
217 (87–461)
280 (58–1318)
< 0.0001
KRAS WT
Mutant
Missing
228 (54)
149 (35)
49 (12)
280 (84–1318)
237 (87–1027)
395 (58–11317)
0.012*
BRAF WT
Mutant
Missing
304 (71)
38 (9)
84 (20)
257 (84–1318)
285 (105–1314)
339 (58–1317)
0.35*
*P-value for complete data.
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cell clones (KRAS G13D and KRAS wt), in which either 
the wild-type or mutant KRAS allele has been disrupted 
[38]. We did a comparative soft-agar colony formation 
assay where we found that in the DLD-1 cell clone with 
the wild-type KRAS allele (KRAS wt), the number of 
colony forming units (CFU) formed after 21 or 28 days 
incubation, respectively, was not affected by the continuous 
presence of TIMP-1 in the growth media (5 μg/mL 
rTIMP-1) (Figure 4A and 4C, 21 days P > 0.999; 28 days 
P = 0.98, respectively). However, in the case of the DLD-1 
table 2: univariate and multivariate cox analyses of PFs and os in the 426 patients with metastatic 
colorectal cancer (389 with progression, 285 deaths) included in the nordIc VII study according 
to pre-treatment plasma tIMP-1 and clinical parameters
Progression-free survival overall survival
univariate cox analyses Multivariate cox analyses univariate cox analyses Multivariate cox analyses
Hr 95% cI p-value Hr 95% cI p-value Hr 95% cI p-value Hr 95% cI p-value
Cetuximab Yes vs No 1.05 0.85–1.29 0.68
0.501
1.142
1.333
1.274
0.27–0.91
0.80–1.63
0.81–2.19
0.87–1.84
b 1.09 0.85–1.40 0.48
0.481
1.082
2.163
0.834
0.25–0.93
0.72–1.63
1.07–4.33
0.52–1.03
a
Plasma TIMP-1 (log)* 1.22 1.07–1.39 0.003
0.845
1.046
2.157
1.158
0.63–1.12
0.80–1.34
1.04–4.42
0.81–1.62
b 1.55 1.33–1.80 < 0.0001
1.045
1.596
4.457
1.228
0.76–1.42
1.17–2.15
1.73–11.48
0.83–1.79
a
Age per 10 years 0.94 0.84–1.04 0.23 0.92 0.82–1.03 0.14 0.97 0.86–1.09 0.60 1.00 0.88–1.14 0.97
Gender,
Female vs. Male 1.08 0.88–1.32 0.46 0.92 0.74–1.13 0.41 0.94 0.74–1.19 0.61 1.16 0.90–1.49 0.26
BRAF Mutant vs. WT 2.00 1.41–2.82 < 0.0001 1.73 1.29–2.33 < 0.0001 3.31 2.30–4.77 < 0.0001 4.74 3.10–7.23 < 0.0001
KRAS Mutant vs WT 1.12 0.90–1.39 0.30
1.049
2.3710
1.3411
1.2712
0.74–1.46
1.29–4.37
0.97–1.85
0.74–2.20
b 0.98 0.76–1.27 0.88
1.149
2.5610
1.7611
0.6712
0.78–1.66
1.30–5.06
1.16–2.66
0.33–1.41
a
Metastatic sites
> 1 vs 1 1.41 1.13–1.76 0.0026 1.43 1.13–1.81 0.0034 1.59 1.22–2.08 0.0006 1.60 1.20–2.14 0.0015
WHO PS ≥ 1 vs 0 1.61 1.30–1.99 < 0.0001 1.33 1.05–1.68 0.020 1.88 1.47–2.39 < 0.0001 1.52 1.16–1.98 0.0023
Serum CRP,
Elevated vs. normal 1.50 1.22–1.85 0.0002 1.44 1.12–1.86 0.0046 1.61 1.25–2.05 0.0002 1.27 0.94–1.71 0.11
Serum CEA, 
Elevated vs. normal 1.63 1.24–2.14 0.0004 1.39 1.03–1.88 0.034 1.93 1.38–2.71 0.0001 1.70 1.19–2.44 0.0038
HR = Hazard ratio. CI = Confidence interval. *Plasma TIMP-1 was included as a log transformed continuous variable (log base 2). 
aP = 0.004 for the interaction Treatment X KRAS X TIMP-1.
bP = 0.096 for the interaction Treatment X KRAS X TIMP-1.
1HR for Cetuximab vs no cetuximab for KRAS mutant and TIMP-1 level at the 3rd quartile (409 ng/ml).
2HR for Cetuximab vs no cetuximab for KRAS WT and TIMP-1 level at the 3rd quartile (409 ng/ml).
3HR for Cetuximab vs no cetuximab for KRAS mutant and TIMP-1 level at the 1st quartile (201 ng/ml).
4HR for Cetuximab vs no cetuximab for KRAS WT and TIMP-1 level at the 1st quartile (201 ng/ml).
5HR for 2-fold difference TIMP-1 levels for mutant KRAS treated with Cetuximab.
6HR for 2-fold difference TIMP-1 levels for WT KRAS treated with Cetuximab.
7HR for 2-fold difference TIMP-1 levels for mutant KRAS not treated with Cetuximab.
8HR for 2-fold difference TIMP-1 levels for WT not treated with Cetuximab.
9HR for KRAS mutant vs WT receiving cetuximab and TIMP-1 level at the 3rd quartile (409 ng/ml).
10HR for KRAS mutant vs WT not receiving cetuximab and TIMP-1 level at the 3rd quartile (409 ng/ml).
11HR for KRAS mutant vs WT receiving cetuximab and TIMP-1 level at the 1st quartile (201 ng/ml).
12HR for KRAS mutant vs WT not receiving cetuximab and TIMP-1 level at the 1st quartile (201 ng/ml).
For OS, a significant interaction between KRAS, TIMP-1 level and treatment with Cetuximab is demonstrated, P = 0.006 in a 
multivariable model, for PFS the same analysis gives p = 0.078, although not significant, the analysis is retained.
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clone with the KRAS-mutated allele (KRAS G13D), we 
observed an increase in the number of formed cell foci 
after 21 and 28 days incubation, respectively (Figure 4A 
and 4C, 21 days P = 0.04; 28 days P = 0.03, respectively). 
As expected, cells bearing the KRAS G13D mutated allele 
displayed increased ability to form colonies in soft agar, when 
compared to the clone with the KRAS wt allele (Figure 4B 
and 4D, respectively). The interaction between cell line 
and TIMP-1 exposure was non-significant at 21 days 
(P = 0.06), but it was significant after 28 days (P = 0.04).
tIMP-1 enhances crc cell invasion in a KRAS 
mutation dependent manner
A previously published study reported that TIMP-1 
can induce a more aggressive phenotype in pancreatic 
ductal cells, but does so specifically in KRAS-mutated 
(G12D) cells [39]. To determine if TIMP-1 could promote 
invasion in a KRAS-dependent manner in CRC cells, 
we stimulated the matched pair of isogenic DLD-1 cell 
clones (KRAS G13D and KRAS wt) with exogenously 
added recombinant TIMP-1 (rTIMP-1; 5 μg/mL) [40] and 
compared the invasive potential of these cells to that of a 
control group (no added rTIMP-1), in a Boyden chamber 
invasion assay. We found an interaction between addition 
of rTIMP-1 and KRAS mutational status (Figure 4E). 
Whereas the DLD-1 cell clone bearing a wt-type KRAS 
allele  showed no significant difference in invasive 
potential in the presence, or not, of TIMP-1 (Figure 4E; 
P = 0.999), KRAS mutated cells (KRAS G13D) responded 
to the presence of TIMP-1 in the growth medium 
(5.0 µg/mL rTIMP-1), becoming significantly more 
invasive (Figure 4E; KRAS G13D P = 0.0152). The 
invasive potential of DLD-1 KRAS mutated cells upon 
stimulation with TIMP-1, compared with the BSA 
control, was significantly different to that of KRAS wt cells 
(P = 0.0328) (Figure 4E). These results indicate that under 
the conditions of the assay, TIMP-1 promotes invasion 
only in KRAS-mutated cells.
Given that TIMP-1 can promote cell proliferation 
and survival, we examined the cell cycle profile of KRAS 
wt and KRAS G13D mutated CRC cells stimulated or 
not with TIMP-1. We found that, although there were 
significant differences in cell-cycle profile between the 
two cell lines, exposure to TIMP-1 did not alter the cell-
cycle profile of either cell line to any noticeable degree 
(Figure 5A). We then determined cell viability by the 
crystal violet assay. As shown in Figure 5B, exposure to 
TIMP-1 did not change cell viability of KRAS wt, but we 
could observe a dose-dependent effect on cell viability of 
KRAS G13D mutated CRC cells. Although, this effect was 
not statistical significant, the trend towards increased cell 
viability of KRAS G13D mutated CRC cells, but not KRAS 
wt cells, was consistent with the effects we had observed 
on cell invasion and colony formation.
Identification of KRAS-mutation specific targets 
upon cell exposure to tIMP-1
To address the molecular mechanisms underlying 
the KRAS mutation dependent, TIMP-1 associated effects 
on CRC cells, we performed gene expression profiling of 
KRAS wt and KRAS G13D mutated CRC cells stimulated 
or not with TIMP-1. We then performed a supervised 
comparative analysis of the results using a predefined 
set of criteria: to be considered, genes should show 
differential expression in KRAS G13D mutated cells upon 
stimulation with TIMP-1, but no significant differences 
in KRAS wt cells. In addition, their baseline expression 
in KRAS G13D mutated cells should not be significantly 
different from KRAS wt cells. Finally, genes should be 
categorized under the gene ontology term “Ras protein 
signal transduction”. We identified five genes (Table 3) 
that fulfilled these criteria: RAF1 (RAF proto-oncogene 
serine/threonine-protein kinase), MAP3K11 (MLK3; 
mitogen-activated protein kinase kinase kinase 11), 
MAP3K3 (MEKK3; mitogen-activated protein kinase 
kinase kinase 3), MAP3K6 (ASK2; mitogen-activated 
protein kinase kinase kinase 6), and MAP4K2 (GCK; 
mitogen-activated protein kinase kinase kinase kinase 2). 
Suggestively, the five genes we identified in this manner 
are all involved in the RAS-JNK-p38 MAPK signaling 
axis (Figure S3), one of the signaling pathways related 
to RAS signaling and a key transduction pathway in 
CRC [41, 42], thus providing a molecular elucidation for 
our observations. A more comprehensive analysis of the 
transcriptomic, as well as functional proteomic changes, 
that take place in KRAS G13D mutated cells upon 
stimulation with TIMP-1 is ongoing, and will be reported 
elsewhere.
dIscussIon
Our laboratory has throughout the years published 
a number of articles that point to TIMP-1 as a potentially 
valuable biological marker, be it for early detection, 
prognosis, or predictive of therapy outcome in CRC 
[27, 29, 30, 43, 44]. TIMP-1 is an endogenous inhibitor 
of metalloproteinases, a family of proteins that play a 
role in tumor invasion and metastases. But in addition 
to its canonical MMP-inhibitory function, TIMP-1 
can stimulate cell proliferation and prevent apoptosis, 
independently of the presence of the MMP inhibitory 
domain; it has been shown that binding of TIMP-1 to 
the cell surface can signal through RAS, to activate 
the PI3K/AKT signal pathways, and also that EGF 
signaling can induce TIMP-1 expression [36, 37, 45, 46]. 
The multiple level of interactions that exist in EGF 
signaling, RAS, and cell survival, proliferation and 
invasion, indicated that high plasma TIMP-1 levels may 
interact with EGFR signaling and thereby affect the 
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anti-tumor effects of EGFR inhibitors. We investigated 
the association between plasma TIMP-1 levels and 
clinical outcome in patients treated with a regimen based 
on an oxaliplatin backbone adding (or not) cetuximab 
(the NORDIC VII Study). The results, presented here, 
showed an association between high plasma TIMP-1 
levels and benefit from adding cetuximab to the standard 
(FOLFOX) treatment regimen in patients bearing KRAS 
mutated tumors (Figure 1 and Table 2), identifying 
plasma TIMP-1 levels as a novel predictive biomarker for 
cetuximab response in KRAS mutated tumors (Figure 2). 
We were also able to confirm a strong prognostic effect of 
plasma TIMP-1 levels irrespective of treatment (Figure 1 
and Table 2), which reiterates previously reported data 
that plasma TIMP-1 is a prognostic biomarker in mCRC 
patients receiving oxaliplatin-containing treatment [30]. 
But it is not straightforward to reconcile these 
observations with TIMP-1’s biological functions. Neither 
table 3: Genes differentially up-regulated in KRAS-mutated cells in the presence of rtIMP-1 
(5 μg/mL) as compared to KRAS-wild-type bearing cells
Gene Log2Foldchange P-value
KRAS wt  
vs  
KRAS G13D
KRAS wt  
vs  
KRAS wt +TIMP-1
KRAS G13D  
vs  
KRAS G13D +TIMP-1
KRAS wt  
vs  
KRAS G13D
KRAS wt  
vs  
KRAS wt +TIMP-1
KRAS G13D  
vs  
KRAS G13D +TIMP-1
RAF1 −0.05 0.01 1.93 0.9291 0.9834 0.0068
MAP3K11 −0.58 0.05 2.20 0.3576 0.9340 0.0036
MAP3K3 −0.21 −0.09 1.64 0.6709 0.8587 0.0056
MAP3K6 −0.40 0.03 2.10 0.5012 0.9612 0.0035
MAP4K2 0.18 0.22 1.63 0.7054 0.6521 0.0047
Figure 1: Kaplan-Meier estimates of survival probabilities for PFS (A), and OS (B) stratified by pre-treatment plasma 
tIMP-1. Plasma TIMP-1 was categorized according to its tertile levels. P values calculated by log-rank test.
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Figure 2: Kaplan-Meier estimates of survival probabilities. (A) OS probabilities were estimated for patients treated, or not, with 
cetuximab (+/− cetuximab) stratified by KRAS status (KRAS wt or mutant) and TIMP-1 level, below 201 ng/ml (first quartile) or above 
409 ng/ml (third quartile). (b) The estimated survival probabilities based on the multivariable Cox regression model. The covariates are set 
to: CEA status (elevated), CRP (elevated), gender (male), age (70 years), multiple metastatic sites, good performance status (WHO PS 0–1), 
BRAF wt, treatment (cetuximab or not), KRAS status (wt or mutant), and TIMP-1 level equal to 201 ng/ml (first quartile) or equal to 
409 ng/ml (third quartile).
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of the biological activities previously ascribed to TIMP-1, 
be it the canonical MMP-dependent or the MMP-
independent function, can directly explain the association 
we found between high plasma TIMP-1 levels and benefit 
from cetuximab treatment in KRAS mutated tumors. If 
anything, the PI3-K/AKT associated pro-survival effect 
should be deleterious for cetuximab-treated patients, as 
well as being independent of KRAS status. To address this 
issue, we examined the expression and cellular effect(s) 
of TIMP-1 in CRC cells upon stimulation with EGF, and 
in cells bearing, or not, a KRAS-mutated allele. We found 
that TIMP-1 expression could be stimulated by exposing 
CRC cells to EGF ligand in a dose-dependent manner 
(Figure 3). This effect was directly related to expression 
levels of EGFR (Figure S2), showing that the EGF-
ligand/EGFR signaling axis plays an important regulatory 
role in TIMP-1 expression in CRC cells. We could also 
ascertain that TIMP-1 promoted colony formation and 
cell invasion in KRAS-mutated cells, but not in KRAS 
wt cells (Figure 4), consistent with potentiation by 
TIMP-1 of aggressive behavior specifically in KRAS 
mutated cells. This bimodal interaction between EGF-
EGFR signaling and TIMP-1 expression on the one 
hand, and TIMP-1 mediated stimulation of cell invasion, 
specifically on KRAS-mutated cells, on the other hand, 
suggested that the predictive value of TIMP-1 we 
observed is the outcome of two additive effects; first 
that TIMP-1 expression is under control of EGFR-
signaling, independently of the RAS/MAPK-axis 
(Figures 3 and S2), and secondly that TIMP-1 potentiates 
Figure 3: EGF induces tIMP-1 expression in crc cells. CRC cell lines were serum-deprived for 24 h prior to being stimulated 
with either 10 ng/mL or 50 ng/mL EGF for 24h and 48h. Controls, cultured with or without serum, were included in parallel. Immunoblotting 
of cell lysates was carried out using antibodies against P-AKT (Ser374), total AKT, TIMP-1 and p150Glued (normalizing control). (A and b) 
Upper panels: immunoblots of HT-29 and HCT-15, respectively, lower panel: graph depicting pooled densitometry measurements of 
TIMP-1 levels relative to those of p150Glued. Data points are presented as mean ± SEM of triplicate experiments. (c–E) graph depicting 
pooled densitometry measurements of TIMP-1 levels relative to those of p150Glued in immunoblots from DLD-1, SW620, and Colo-205, 
respectively.
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Figure 4: tIMP-1 promotes malignant behavior of KRAS mutated cells. (A–d) TIMP-1 promotes colony formation in soft agar 
in KRAS-mutated cells. Tumorsphere formation was quantified [in colony forming units (CFUs)] for DLD-1 clones bearing either a KRAS-
mutated allele (KRAS G13D) or a wild-type allele (KRAS wt) after 21 and 28 days of growth, in the presence of either rTIMP-1 (5 mg/mL) 
or BSA (control). Visible colonies were counted by two independent observers. Data represents mean ± SEM (error bars), of triplicate 
experiments. Significance was evaluated by two-way ANOVA with Sidak’s multiple comparison post-test. Images were captured at 
10 × magnification. (E) DLD-1 isogenic cell lines were serum-starved for 24 h before assessing the effect of TIMP-1 (5 mg/mL) on invasion 
in a 14-hour Boyden chamber invasion assay. Graph depicts the mean number of invaded cells of triplicate experiments. Invaded cells were 
counted independently by two different observers. Significance was determined by two-way ANOVA with Sidak’s multiple comparison 
post-test. Images were acquired at 10× magnification.
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an aggressive behavior in KRAS mutated cells but not 
KRAS wt cells (Figure 4). The latter effect is presumably 
brought about by the increased expression of downstream 
effectors in the RAS- JNK- p38 MAPK pathway we 
observed in KRAS G13D mutated cells stimulated 
with TIMP-1 (Table 3). When tumor cells are exposed 
to cetuximab, expression of TIMP-1 will be inhibited, 
irrespective of KRAS status. This will not have a 
noticeable effect on KRAS wild-type tumor cells, but will 
reduce the stimulatory drive of extracellular TIMP-1 on 
KRAS mutated tumor cells. These two levels of interaction 
are required to fully account for the predictive value of 
TIMP-1 specifically in cetuximab-treated KRAS-mutated 
patients. From a mechanistic point of view, and taking 
into account the results of our gene expression analysis, 
the effect of TIMP-1 will not be particularly striking in 
patients treated with cetuximab as monotherapy, but will 
do so whenever a chemotherapeutic component is used, 
as the effect on the JNK/p28 MAPK pathway will be 
significant under these conditions, which is in line with 
previous studies from our laboratories [29, 47].
It should be noted that, because our analysis 
was conducted retrospectively, and the NORDIC VII 
trial was not specifically designed, and powered, to 
assess the clinical activity of cetuximab in biomarker-
specific subgroups, these results need to be validated in 
an independent cohort of patients with mCRC. In the 
meantime, this has proven to be a very difficult task, as 
the most recent clinical trials on anti-EGFR therapies 
exclude KRAS-mutated patients, and the original ones, 
which included KRAS-mutated patients, no longer have 
available biological material suitable for analysis of TIMP-
1. Overall, our data provides a strong rationale to study the 
value of TIMP-1 as a predictive biomarker for benefit from 
EGFR-inhibition therapy in patients bearing KRAS mutated 
tumors and we are currently planning such a clinical study.
Figure 5: tIMP-1 does not affect cell cycle progression. DLD-1 clones bearing a KRAS-mutated allele (KRAS G13D) or a wild-
type allele (KRAS wt), were grown in the presence of either rTIMP-1 (5 mg/mL) or BSA (control) and subsequently either subjected to (A) 
cell cycle analysis or (b) cell proliferation. (A) The cell cycle phase distributions after exposure to TIMP-1 or BSA for 24 h were evaluated 
by FACS and are presented as histograms. (B) Cells treated with rTIMP-1 (0.5 or 5 µg/mL) for 48 h and cell proliferation was assessed by 
a crystal violet proliferation assay. Data represents the mean ± SEM of three independent assays.
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MAtErIALs And MEtHods
cell lines and culturing conditions
The colorectal cancer cell lines SW620 and Colo205 
were purchased from the American Tissue Culture 
Collection (Rockville, MD, USA), while the HCT-15 
and HT-29 were obtained from the NCI/Development 
Therapeutics Program. The DLD-1 cell line and matched 
pair of isogenic DLD-1 cell clones (KRAS G13D and 
KRAS wt) [38] were a kind gift from Bert Vogelstein 
(Howard Hughes Medical Institute, The Johns Hopkins 
Medical Institution, USA). DLD-1 and derivative clones 
were cultured in McCoy’s 5A medium supplemented 
with 10% fetal bovine serum (FBS); all other lines were 
cultured in RPMI-1640 medium supplemented with 10% 
FBS. All cells were maintained in cell culture flasks (TPP, 
Transadingen, Switzerland) at 37°C in a humidified, 5% 
CO2 atmosphere under sterile conditions. All cell culture 
media were from Life Technologies (CA, USA), and 
plasticware was from Nunc (Thermo Fischer Scientific, 
USA). Cell identity was verified by short tandem repeat 
(STR) loci analysis at IdentiCell (Aarhus, Denmark). Cells 
were regularly tested for mycoplasma infection (Minerva 
Biolabs, Germany).
For EGF stimulation assays, cells were plated 
overnight, washed twice in PBS to remove serum remnants, 
and subsequently serum-starved in serum-free growth 
media for 24 h, after which fresh serum-deprived medium 
containing human recombinant EGF (rEGF) (Sigma 
Aldrich, MO, USA) at 10 or 50 ng/mL was added and cells 
cultured for an additional 24 h or 48 h period. As controls, 
equivalent concentrations of rEGF solvent (acetic acid) 
or 10% FBS were added in each case, respectively. When 
relevant, recombinant TIMP-1 [40] was added at the stated 
concentrations.
sds-PAGE and Western blot analysis
Whole cell extracts were obtained by lysis of 
70–80% confluent cells. Briefly, cells were washed with 
ice-cold PBS before on-plate lysis with 250–500 µL 
M-PER Mammalian Protein Extraction Reagent (Thermo 
Scientific, MA, USA) containing Pierce Protease and 
Phosphatase Inhibitor Mini Tablets (Thermo Scientific, 
MA, USA). The lysates were centrifuged at 14000 × g 
for 10 min to remove cell debris and total protein 
concentrations of the samples were measured using a 
BCA protein Assay Kit (Novagen, CA, USA) according 
to manufacturer’s instructions. For analysis, equivalent 
amounts of total protein (20 µg per well) were subjected 
to SDS-PAGE separation under reducing conditions. 
Resolved proteins were blotted onto 0.2 µm nitrocellulose 
membranes (Bio-Rad, CA, USA), and blocked in 5% milk 
or BSA (antibody-specific) in Tris-Buffered Saline and 
Tween 20 (TBS-T, 0.05%) for 1 hour at room temperature. 
The membranes were incubated overnight with relevant 
primary antibodies diluted in 5% milk blocking solution 
(p150Glued, and VT-7), or 5% BSA [phospho-AKT(Ser374), 
and AKT] in TBS-T at 4°C. After washing thrice for 
10 min in TBS-T, followed by detection of immune 
complexes with corresponding horseradish peroxidase-
labeled species specific antibodies (Dako, Denmark), 
detection of immune complexes was done using the 
Amersham ECL-Select Western Blotting detection reagent 
(GE Healthcare Life Sciences, NJ, USA) or Clarity 
Western ECL Substrate (Bio-Rad, CA, USA) according to 
manufacturer’s instruction and images were captured with 
a BioSpectrum Imaging system (Ultra-Violet Products, 
CA, USA). The anti-p150Glued antibody was from BD 
Biosciences (NJ, USA), the anti-TIMP-1 antibody was 
an in-house antibody (VT-7) previously described [48], 
and the anti- phospho-AKT (Ser374) and AKT antibodies 
were from Cell Signaling Technologies (MA, USA). Band 
intensity was evaluated by densitometric measurements 
with Image J software (National Institutes of Health).
In vitro invasion assay
In vitro invasive potential was determined using 
Corning® Biocoat™ Matrigel® invasion chambers 
(VWR, Radnor, PA, USA) according to manufacturer’s 
instructions. Briefly, cells were serum-starved for 24 h, 
harvested by trypsin-EDTA treatment, resuspended in 
serum-free medium containing trypsin inhibitor according 
to manufacturer’s instructions (Sigma Aldrich, MO, USA), 
and centrifuged to form a cell pellet  (Sigma Aldrich, 
MO, USA). The cells were washed twice in serum-
free medium, resuspended, and inoculated at a density 
of 500000 cells/500 µL/chamber onto an 8 μm pore 
Matrigel®-coated membrane. The inserts were inset 
in 24-well plates, with each well filled with 750 μl of 
medium containing 50 ng/mL EGF as chemoattractant, 
and subsequently incubated at 37°C for 14 h. After 
incubation, non-invasive cells were carefully scraped 
off with a cotton swab and invasive cells were fixed in 
100% methanol, stained with 10% Giemsa, and counted 
with a light microscope by two independent observers. 
Four independent experiments were performed, each with 
technical duplicates, in all experimental conditions. Mean 
values of the duplicates were used for statistical analysis.
soft agar clonogenic assay
To assess a potential differential biological 
effect of TIMP-1 on anchorage-independent growth in 
KRAS mutated cells, a double layer soft agar assay was 
performed. Monolayer cultures of DLD-1 isogenic cells 
(KRAS (wt) and (KRAS (G13D)) were prepared into 
single-cell suspensions using 0.01% trypsin-EDTA. 
The cells were suspended in growth medium containing 
0.18% low melting temperature agar (Sigma Aldrich, 
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MO, USA) supplemented with either 5 μg/mL BSA or 
rTIMP-1, seeded at a density of 800 cells/750 μL/well on 
top of a solidified bottom layer of 0.75% agar in growth 
medium with 5.0 μg/mL rTIMP-1 or BSA (control) 
in 12-well plates. The following day 500 μL growth 
medium containing TIMP-1 or BSA in corresponding 
concentrations was added. Each condition was set up in 
triplicate and three independent assays were performed. 
Visible colonies were counted independently by two 
observers after 21 and 28 days.
cell viability and FAcs assays
DLD-1 isogenic cells KRAS (wt/−) and KRAS 
(−/G13D) were plated on 6-well tissue culture plates, 
washed twice in PBS to remove serum, and serum starved 
in 2 mL McCoy’s 5A medium for additional 24 h to 
synchronize the cells. rTIMP-1 (5 µg/mL) or BSA were 
added and cells incubated for 24 h. Cells were seeded at 
concentrations such that they would reach approximately 
70% confluency when measured, corresponding to 200000 
and 220000 cells/well for KRAS (wt) and KRAS (G13D), 
respectively. Cells were collected by trypsinisation, 
washed briefly in serum-free McCoy’s 5A medium 
containing trypsin inhibitor (diluted 1:100), and fixed and 
permeabilized by adding 700 µL ice-cold 96% ethanol 
on ice with intermittent vortexing every 10 min. Prior to 
analysis, cell samples were centrifuged at 1200 rpm for 
5 min and cell pellets resuspended in 200 µL propidium 
iodide (PI) containing buffer with RNase, and incubated 
for 30 min. The samples were analysed in a flow cytometer 
(BD FACSVerse) set for PI acquisition. We used pulse-
width/pulse-area to discriminate between cells in G2/M 
and cell doublets with the intent to gate out the latter. The 
data was analysed using FlowJo software.
For cell viability/proliferation we used a standard 
crystal violet assay. Briefly, cells were plated at a density 
of 25000 cells/well in 24-well plates, and grown in 
serum-free medium for 4 h. TIMP-1 was then added to 
the medium to reach final concentrations of 0.5 µg/mL 
or 5 µg/mL. Two controls were run in parallel: 5 µg/mL 
BSA (Roche Diagnostics, Basel, Switzerland) and PBS 
(rTIMP-1 vehicle). Cells were allowed to proliferate for 
48h, washed thrice with PBS, and stained with 200 µL of 
a 0.5% solution of crystal violet.
Gene expression analysis
DLD-1 isogenic cells (KRAS (wt/−) and (KRAS (−/
G13D)) were plated and serum-starved for 3 h in medium 
containing 1% FBS, prior to exposure to TIMP-1. Cells 
were stimulated with 5 µg/mL rTIMP-1 for 4 h, washed 
and RNA was extracted using RNeasy mini-kit according 
to the manufacturer’s protocol (Qiagen, CA, USA). 
Samples were prepared for analysis using Low 
Input Quick Amp Labeling Kit, one-color (Agilent 
Technologies, CA, USA) according to manufacturer’s 
instructions. Labelled cDNA was purified and hybridized 
to the Agilent one-color human whole genome microarray 
chip, which was analyzed using Agilent Feature Extraction 
Software (Agilent Technologies). Samples were clustered 
by calculating pairwise distances followed by clustering 
by the ‘ward’ method. Log2FoldChange of KRAS wt 
vs KRAS G13D mutated cells, as well as of untreated 
vs treated cells, and their corresponding p-values were 
calculated using moderated t-test. Genes were considered 
significantly differentially expressed if p-value < 0.0075 
and Log2FoldChange > +/−1.
Patient characteristics and analysis
In the NORDIC VII study [34] 566 patients with 
mCRC were included from 32 Nordic centers. The baseline 
demographic characteristics of the 426 patients with a pre-
treatment plasma TIMP-1 measurement are shown in Table 1. 
All patients provided written informed consent, and the 
study (including biomarker analyses) was approved by the 
Regional Ethics Committee (VEK ref. 20050053). 
Patients were randomized between; Nordic FLOX: 
5-FU i.v. bolus 500 mg/m2 and folinic acid 60 mg/m2 
day 1–2, oxaliplatin 85 mg/m2 day 1 every two week 
until progression (arm A); Nordic FLOX plus cetuximab 
(400 mg/m2 day 1, then 250 mg/m2 weekly) until 
progression (arm B) or Nordic FLOX + cetuximab for 
16 weeks, and weekly cetuximab as maintenance treatment 
until progression (arm C). Main inclusion criteria were: 
histologically confirmed mCRC (adenocarcinomas); age 
> 18 years and < 75 years; WHO performance status (PS) 
≤ 2; no prior chemotherapy for mCRC, non-resectable and 
measurable disease according to the Response Evaluation 
Criteria in Solid Tumors (RECIST version 1.0); last 
adjuvant chemotherapy ≥ 6 months before inclusion; no 
previous oxaliplatin treatment; adequate haematological, 
renal and liver function.
The patients were treated until disease progression and 
followed until death or 30th April 2009. Pre-treatment plasma 
sample were available from 426 (75%) patients at baseline. 
Further details about the study have been published [34]. 
Survival probabilities for overall survival were estimated by 
the Kaplan-Meier method and tests for differences between 
strata were done using the log-rank statistic. P-values less 
than 5% were considered statistically significant. Statistical 
calculations were performed using SAS (version 9.2, SAS 
Institute, Cary, NC, USA) and R [49].
statistical analysis of nordIc VII data
The primary clinical endpoint for this biomarker 
study was overall survival (OS) determined as the time 
from randomization to treatment in NORDIC VII study 
to time of death by any causes. The median follow-up 
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time was 37 month (24–53 months). Cases in which 
patients were alive at this date were censored. Secondary 
endpoint was progression-free survival (PFS) (primary 
endpoint of the NORDIC VII study) defined as the time 
from randomization until objective disease progression. 
Descriptive statistics are presented as median levels 
and ranges. Analyses of measurements for PFS and OS 
were done using the Cox proportional hazards model. 
As the analyses performed comparing treatment arms 
did not reveal any substantial differences in terms of OS 
and PFS between the original study population and this 
subset of patients (please see below), we found it justified 
to pool arms B and C (i.e. + cetuximab treatment) for 
the statistical analyses. Thus, patients were stratified as 
receiving cetuximab or not, i.e. arm B and C versus arm A. 
Survival probabilities for OS were estimated by the 
Kaplan-Meier method and tests for differences between 
strata were done using the log-rank statistic. Graphical 
presentation using Kaplan-Meier estimates of PFS and OS 
was shown grouping patients in tertiary TIMP-1 levels. 
Multivariable analysis of PFS and OS was done using the 
Cox proportional hazard model. TIMP-1 concentrations in 
plasma were entered by the actual value on the log scale 
(base 2). Missing values for CEA (n = 27), CRP (n = 22), 
BRAF (n = 101) and KRAS (n = 62) were categorized 
separately and included in the final multivariable analysis. 
The final model included a three way interaction term 
(treatment +/− cetuximab +/− x KRAS mutational status 
x plasma TIMP-1). The model was assessed using 
Schoenfeld and Martingale residuals. In particular, the 
linearity assumption for plasma TIMP-1 on the log scale 
was evaluated using the supremum test for the cumulated 
martingales [50]. The results yielded P > 0.05 testing for 
the linearity of plasma TIMP-1 on the log scale. Ten-fold 
cross validation performed in order to assess over-fitting 
[51] showed almost similar results for the training and 
test sets (data not shown). P-values less than 5% were 
considered statistically significant. Statistical calculations 
were performed using SAS (version 9.2, SAS Institute, 
Cary, NC, USA) and R [49]. The results of this project are 
reported in accordance with the REMARK guidelines [52].
biomarker analyses
Total plasma TIMP-1 levels (free and in complex 
with matrix metalloproteinase) were determined using the 
MAC15 antibody kinetic enzyme-linked immunosorbent 
assay (ELISA) as described [35]. Duplicate measurements 
were carried out and the mean values were used for 
statistical analysis. The mean intra-assay coefficient of 
variation (CV) was 5.1% (range 1.5%–9.8%) and the inter-
assay CV was 6.7%. Data on serum carcinoembryonic 
antigen (CEA), C-reactive protein (CRP), KRAS and BRAF 
mutational status of the tumor, WHO performance status 
(PS), and number of metastatic sites were retrieved from 
the original study report [34].
statistical analysis of in vitro data
One-way ANOVA tests were conducted to compare 
the mean intensity of the bands of western blots within 
one cell line after treating the cells with rEGF. For colony 
formation and Boyden chamber assyas, a two-way 
analysis of variance (ANOVA) was used to compare the 
mean of samples that are influenced by two variables: 
namely i) cell line (KRAS status) and ii) the experimental 
condition (rTIMP-1 or BSA). Multiple comparisons post 
tests were applied to counteract the risk of type I errors 
when conducting multiple comparisons. GraphPad Prism 
(GraphPad Software, USA) was used for one-way and 
two-way analyses of variance (ANOVA) and P-values 
were adjusted for multiplicity. 
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